SCHEMBL19917022

SCHEMBL19917022

O=C1CCC(C(F)(F)F)CC1C(=O)OCc1ccccc1

nearest known ligand 0.43

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.43
ALDH1A1 P00352 1/20 0.41
CYP3A4 P08684 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
TLR4 O00206 1/20 0.39
FABP7 O15540 1/20 0.39
FABP5 Q01469 1/20 0.39
FKBP1A P62942 3/20 0.39
CHRM2 P08172 1/20 0.38
CHRM4 P08173 1/20 0.38
CHRM5 P08912 1/20 0.38
CHRM1 P11229 1/20 0.38
CHRM3 P20309 1/20 0.38
ELANE P08246 4/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL988117 0.82 TSHR (0.51) TSHRALDH1A1CYP3A4CYP2C9CYP2C19
SCHEMBL30032752 0.79 MAPT (0.40) ALDH1A1TLR4
SCHEMBL19917021 0.78 CYP3A4 (0.45) TSHRALDH1A1CYP3A4CYP2C9CYP2C19
SCHEMBL1666324 0.77 CYP3A4 (0.52) TSHRALDH1A1CYP3A4CYP2C9CYP2C19
SCHEMBL5319406 0.76 MCL1 (0.56) TSHRALDH1A1CYP3A4CYP2C9CYP2C19
SCHEMBL2128136 0.76 MCL1 (0.56) TSHRALDH1A1CYP3A4CYP2C9CYP2C19
SCHEMBL31179844 0.74 TLR4 (0.36) ALDH1A1CYP2C9CYP2C19TLR4CHRM2
SCHEMBL24109058 0.72 TSHR (0.47) TSHRALDH1A1FABP7FABP5FKBP1A
SCHEMBL19917036 0.72 ALDH1A1 (0.43) TSHRALDH1A1CYP2C19FABP7FABP5
SCHEMBL19917053 0.72 DDB1 (0.43) TSHRALDH1A1CYP3A4CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3505171-A1 BICYCLIC NITROGENATED HETEROCYCLIC COMPOUND Mitsubishi Tanabe Pharma Corporation (JP) 2019-07-03 EP disclosed
EP-3505171-A1 BICYCLIC NITROGENATED HETEROCYCLIC COMPOUND Mitsubishi Tanabe Pharma Corporation (JP) 2019-07-03 EP disclosed
US-20190185479-A1 BICYCLIC NITROGENATED HETEROCYCLIC COMPOUND MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-06-20 US disclosed
US-20190185479-A1 BICYCLIC NITROGENATED HETEROCYCLIC COMPOUND MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-06-20 US disclosed
WO-2018038265-A1 BICYCLIC NITROGENATED HETEROCYCLIC COMPOUND 田辺三菱製薬株式会社 2018-03-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190185479-A1 BICYCLIC NITROGENATED HETEROCYCLIC COMPOUND PDE7B, PDE3A, PDE7A TSHR 4597/4885ALDH1A1 1644/4885CYP3A4 1274/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.